Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer
- Focus Pharmacogenomic; Pharmacokinetics
- Acronyms CLEARSUN
- 11 Jul 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2010 New trial record